Cigna Investments Inc. New reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,463 shares of the company’s stock after selling 753 shares during the period. Cigna Investments Inc. New’s holdings in Teva Pharmaceutical Industries Limited were worth $447,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. HL Financial Services LLC boosted its position in Teva Pharmaceutical Industries Limited by 35.1% in the second quarter. HL Financial Services LLC now owns 21,239 shares of the company’s stock worth $706,000 after buying an additional 5,516 shares in the last quarter. Pictet Asset Management Ltd. boosted its position in Teva Pharmaceutical Industries Limited by 0.4% in the second quarter. Pictet Asset Management Ltd. now owns 3,026,485 shares of the company’s stock worth $84,318,000 after buying an additional 12,397 shares in the last quarter. TD Asset Management Inc. boosted its position in Teva Pharmaceutical Industries Limited by 4.6% in the second quarter. TD Asset Management Inc. now owns 2,200,584 shares of the company’s stock worth $73,104,000 after buying an additional 96,857 shares in the last quarter. Physicians Financial Services Inc. boosted its position in Teva Pharmaceutical Industries Limited by 5.2% in the second quarter. Physicians Financial Services Inc. now owns 12,108 shares of the company’s stock worth $402,000 after buying an additional 600 shares in the last quarter. Finally, Cullen Frost Bankers Inc. boosted its position in Teva Pharmaceutical Industries Limited by 4.8% in the second quarter. Cullen Frost Bankers Inc. now owns 12,056 shares of the company’s stock worth $401,000 after buying an additional 555 shares in the last quarter. Hedge funds and other institutional investors own 56.04% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.49 on Thursday. Teva Pharmaceutical Industries Limited has a 12 month low of $16.81 and a 12 month high of $53.96. The firm’s market capitalization is $17.77 billion. The firm has a 50-day moving average price of $28.36 and a 200 day moving average price of $31.20.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The firm’s revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 earnings per share. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.94%. The ex-dividend date of this dividend is Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is presently -18.95%.

ILLEGAL ACTIVITY NOTICE: “Cigna Investments Inc. New Has $447,000 Stake in Teva Pharmaceutical Industries Limited (TEVA)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/cigna-investments-inc-new-has-447000-stake-in-teva-pharmaceutical-industries-limited-teva/1497578.html.

A number of equities analysts have weighed in on the company. BidaskClub cut Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a report on Wednesday. Citigroup Inc. cut Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $32.00 to $19.00 in a report on Wednesday. Zacks Investment Research cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Three research analysts have rated the stock with a sell rating, twenty have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $36.73.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.